ACCREDO® SPECIALTY PHARMACY

Converting brand drugs to generics



EVERNORTH HEALTH SERVICES

Confidential, unpublished property of Evernorth Health Services. Do not duplicate or distribute.
Use and distribution limited solely to authorized personnel. © 2026 Evernorth Health Services.

Patent expiration landscape

Significant opportunity within the next five years

2026-2030
$137B



EVERNORTH HEALTH SERVICES

Confidential, unpublished property of Evernorth Health Services. Do not duplicate or distribute.
Use and distribution limited solely to authorized personnel. © 2026 Evernorth Health Services.

KEY BRAND DRUGS LOSING PATENT PROTECTION

$137B+ market within the next five years

SPECIALTY
$68B

2026 | $43B	2027 | $38.5B	2028 | $34.8B	2029 | $12B	2030 | $9B
Adempas ★	Belbuca	Eliquis	Belsomra	Consensi
Atrovent HFA	Cresemba	**Erivedge ★**	**Bendeka ★**	Exparel
Bosulif tablets ★	Dulera	**Kalydeco ★**	**Dovato ★**	**Gocovri ★**
Bridion	Fanapt	Nayzilam	**Empliciti ★**	**Lenvima ★**
Briviact	**Ibrance ★**	**Nexplanon ★**	Eucrisa	Movantik
Farxiga/Xigduo	**Inlyta ★**	Nexterone inj	**Iclusig ★**	Nexletol
Januvia/Janumet	Invokana/Invokamet	**Ninlaro ★**	**Juluca ★**	Nuvessa
Ofev ★	**Jakafi ★**	**Otezla ★**	Lo Loestrin FE	Qbrexza
Opsumit ★	**Kyprolis ★**	Rexulti	**Lynparza ★**	Relistor tablets
Pomalyst ★	Lumigan 0.01%	**Tivicay tablets ★**	**Mektovi ★**	Reyvow
Tradjenta	**Mekinist ★**	**Triumeq ★**	Multaq	Sivextro
Trintellix	**Orenitram★**	**Vyndamax ★**	Prevymis	**Tafinlar ★**
Tyvaso ★	**Uptravi ★**	Vyzulta	**Prezcoxib ★**	**Tobi Podhaler ★**
Velour	**Vivitrol ★**	Winlevi	Viberzi	Veltassa
Xeljanz/XR ★	Xarelto 10, 15 & 20mg	Xifaxin	**Wakix ★**	Vraylar
Xyrem ★	**Xtandi ★**	**Yondelis ★**	Xiidra	

EVERNORTH HEALTH SERVICES

Confidential, unpublished property of Evernorth Health Services. Do not duplicate or distribute.
Use and distribution limited solely to authorized personnel. © 2026 Evernorth Health Services.

Brand to generic conversion

Ongoing, pre-launch—pipeline monitoring and progress reporting

Outcome #1

Patient switches to generic

Outcome #2

Patient stays with brand



1. Educate PRIOR TO GENERIC LAUNCH

+ Manufacturers' suggested service offerings and communications
+ Payers patient impact and opportunity
+ Physicians pipeline awareness

2. Rx received AFTER GENERIC LAUNCH

Outreach to physician for substitutable Rx + clinical conversation with Accredo pharmacist for any questions or concerns

3. Support patient AFTER GENERIC LAUNCH

+ Pharmacy system prompts discussion with patient on change in therapy
+ Transfer to pharmacist if patient has clinical questions
+ Discuss copays and OOP impact
+ If needed, support transaction to available copy assistance[1]

1. Level of available support varies with drug, program and TRC

EVERNORTH HEALTH SERVICES

Confidential, unpublished property of Evernorth Health Services. Do not duplicate or distribute. Use and distribution limited solely to authorized personnel. © 2026 Evernorth Health Services.

Accredo accelerated generic conversion vs. retail for

80%
Accredo conversion rate by September ‘25

32%
Higher conversion vs. retail 6 months post generic entering the market

6+ months
For retail to be at parity with Accredo conversion rates



**Generic conversion for Promacta + Tasigna*

EVERNORTH HEALTH SERVICES

Confidential, unpublished property of Evernorth Health Services. Do not duplicate or distribute. Use and distribution limited solely to authorized personnel. © 2026 Evernorth Health Services.